Antibiotic shows promise in treating extensively drug-resistant tuberculosis

More research needed to avoid adverse events

2012-10-18

(Press-News.org) WHAT:
When tested in patients hospitalized with extensively drug-resistant tuberculosis (XDR-TB) unresponsive to previous treatment, linezolid, an antibiotic used to treat severe bacterial infections, proved largely effective when added to the patients' ongoing TB treatment regimen. Also, few patients developed resistance to the drug. These promising findings were tempered, however, by the fact that 82 percent of the patients who received linezolid experienced significant adverse events that may have been related to the drug. Findings from the study appear in the October 18th issue of the New England Journal of Medicine.
XDR-TB is a form of tuberculosis that is resistant to at least four of the drugs most often used to treat TB. Although XDR-TB is rare, 77 countries worldwide reported at least one case by the end of 2011, according to the World Health Organization. In the United States, at least 57 cases of XDR-TB were reported between 1993 and 2010. Patients infected with XDR-TB typically have very poor clinical outcomes, and with no effective drugs available for their treatment, they often die.
Led by Clifton E. Barry, III, Ph.D., of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and Sang-Nae Cho, D.V.M., Ph.D., professor of infectious diseases at Yonsei University, South Korea, researchers enrolled at two South Korean hospitals patients with chronic XDR-TB who had failed to respond to any treatment during the six months before enrolling into the study. The patients, predominantly men (72 percent) ranging in age from 20 to 64, were randomly assigned either to immediately begin 600 milligrams (mg) of linezolid once daily as part of their existing treatment regimen (19 patients) or to start the drug after a two-month delay (20 patients). After no longer testing positive for the bacterium or after four months of therapy, whichever came first, participants were then randomly assigned for the next 18 months to continue taking either a daily 600-mg dose of linezolid or a daily 300-mg dose. The patients were regularly monitored for any adverse effects.
After four months, 15 of the 19 patients (79 percent) in the immediate-start group, and 7 of the 20 (35 percent) patients in the delayed-start group no longer tested positive for TB. After six months of treatment with the drug, 87 percent (34 of 39 patients) no longer tested positive for the bacterium.
Adverse effects associated with long-term linezolid use included bone marrow suppression and peripheral and optic neuropathy. In the study, 31 patients (82 percent) experienced clinically significant adverse events that were likely related to the use of drug, but most of these events resolved quickly after briefly stopping the drug or using the lower 300-mg dose, the authors note. Only 3 of those 31 patients permanently discontinued use of the drug because of side effects. Additionally, only 4 of the 38 patients (11 percent) who used the drug for six months or more acquired resistance to linezolid. Thirteen patients completed treatment and have not had a relapse in the 12 months after treatment ended. All of the patients continue to be watched for long-term outcomes.
The authors conclude that linezolid may become an important therapeutic option for XDR-TB cases in the future. It also may form part of a regimen to treat MDR-TB in periods shorter than the two years of therapy standard for such patients now. Yet in both instances, additional clinical trials are needed to identify a dosage that is sufficiently potent yet does not cause significant adverse events.
ARTICLE: M Lee et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. New England Journal of Medicine DOI: 10.1056/NEJMoa1201964 (2012).
WHO:
NIAID Director Anthony S. Fauci, M.D., and Clifton E. Barry, III, Ph.D., chief of the Tuberculosis Research Section in NIAID's Laboratory of Clinical Infectious Diseases, are available to discuss this study.
RESOURCE INFORMATION:
NIAID co-funded the study with the Ministry of Health and Welfare, South Korea, under project number 1ZIA AI001067. The study is available at ClinicalTrials.gov under the identifier NCT00727844. Pfizer provided the study drug at no cost.
CONTACT:
To schedule interviews, please contact Sara Crocoll, (301) 402-1663, niaidnews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
### About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/. NIH...Turning Discovery Into Health

ELSE PRESS RELEASES FROM THIS DATE:

A little science goes a long way

2012-10-18

PULLMAN, Wash. - A Washington State University researcher has found that engaging elementary school students in science for as little as 10 hours a year can lead to improved test scores in math and language arts. Samantha Gizerian, a clinical assistant professor in WSU's Department of Veterinary and Comparative Anatomy, Pharmacology and Physiology, saw improved test scores among fourth-grade students in South Los Angeles after students from the Charles R. Drew University of Medicine and Science gave 10 one-hour presentations on science. "A lot of students say things like, ...

Criminal punishment and politics: Elected judges take tougher stance prior to elections

2012-10-18

UNIVERSITY OF CALIFORNIA, BERKELEY'S HAAS SCHOOL OF BUSINESS –The last few months leading up to an election can be a critical, political game changer. One right or one wrong move can quickly change a candidate's standing at the polls. New research suggests that judges who are elected, rather than appointed, respond to this political pressure by handing down more severe criminal sentences – as much as 10 percent longer –in the last three months before an election compared with the beginning of their terms. "We can't say if more severe sentencing is better for society or ...

Non-infected babies born to HIV mothers have reduced immunity to measles

2012-10-18

Non-infected babies born to HIV positive mothers should be vaccinated early against measles, to avoid them acquiring the virus or passing it on to others. A study published in the November issue of Acta Paediatrica found that even if babies are born without HIV, their maternally derived protection against measles may be impaired by their mother's positive HIV status. "The eradication of measles is high on the agendas of the World Health Organization and other international agencies and it is important to define and target any new group of susceptible infants" says ...

Some 500 scientists have created a Top 10 list of plant-damaging fungi

2012-10-18

Almost 500 international experts have worked together to develop a ranking system of the ten most important phytopathogenic fungi on a scientific and economic level. The rice blast fungus (Magnaporthe oryzae) sits at the top of the list. A survey conducted on 495 international researchers resulted in a list contaning the most important phytopathogenic fungi. Each researcher chose three that they thought to be most significant and the most voted then formed the list. Said list has been published in the journal Molecular Plant Pathology and each one of the species mentioned ...

Viruses act like 'self-packing suitcases'

2012-10-18

Researchers at the University of Leeds have identified a crucial stage in the lifecycle of simple viruses like polio and the common cold that could open a new front in the war on viral disease. The team are the first to observe at a single-molecule level how the genetic material (genome) that forms the core of a single-strand RNA virus particle packs itself into its outer shell of proteins. Lead researcher Professor Peter Stockley said their results overturn accepted thinking about the process and could open a chink in the armour of a wide range of viruses. "If we can ...

Scientists harness immune system to prevent lymphoma relapse

2012-10-18

UK scientists hope that lymphoma patients could benefit from a new drug that triggers the cancer-fighting properties of the body's own immune system, after highly promising early laboratory results. The University of Manchester researchers, who were funded by the charity Leukaemia & Lymphoma Research, have shown that, when used in conjunction with radiotherapy, the new drug is potentially four times more likely to lead to long-term survival than radiotherapy alone. Relapse is a common fate for many lymphoma patients and new treatments are desperately needed. The new ...

Genes and immune system shaped by childhood poverty, stress

2012-10-18

A University of British Columbia and Centre for Molecular Medicine and Therapeutics (CMMT) study has revealed that childhood poverty, stress as an adult, and demographics such as age, sex and ethnicity, all leave an imprint on a person's genes. And, that this imprint could play a role in our immune response. The study was published last week in a special volume of the Proceedings of the National Academy of Sciences that looks at how experiences beginning before birth and in the years after can affect the course of a person's life. Known as epigenetics, or the study ...

Female Pulitzer Prize winners require higher qualifications, MU study finds

2012-10-18

COLUMBIA, Mo. —The Pulitzer Prize in Journalism is one of the world's most prestigious awards. Despite progress in the last few decades, gender disparities in the field of journalism have existed as long as the profession has. Now, a University of Missouri researcher has found that female Pulitzer Prize winners are more likely to have greater qualifications than their male counterparts in order to win the coveted award. In a study to be published in Journalism and Mass Communication Quarterly, Yong Volz, an assistant professor of journalism studies in the MU School of ...

College students and credit card debt -- parents at fault?

2012-10-18

Parents need to be good role models to help their children make sensible financial decisions, according to Adam Hancock and his team, from East Carolina University in the US. Their work highlights that parents who argue about finances contribute to increasing credit card debt among their children during their student years. Their work is published online in Springer's Journal of Family and Economic Issues. Credit card debt among college students has been a growing concern for researchers and policymakers over the last decade. In addition, there is growing concern among ...

A cancer diagnosis does not make young people religious

2012-10-18

A sociologist of religion from the University of Copenhagen has interviewed 21 young patients diagnosed with a life-threatening cancer about their religious beliefs. She concludes that a cancer diagnosis will not make young people, who are not religious already, turn to religion. But it can confirm already existing beliefs. "My research shows that young cancer patients' views on existential issues show consistency before and after the diagnosis: Their faith and their religious practices remain the same. However, the beliefs they already had can be confirmed and strengthened ...

LAST 30 PRESS RELEASES:

Project to redesign clinical trials for neurologic conditions for underserved populations funded with $2.9M grant to UTHealth Houston

Menarini Group and Insilico Medicine enter a second exclusive global license agreement for an AI discovered preclinical asset targeting high unmet needs in oncology